IL21R and breast cancer: Methylation levels of IL21R amplicon at all CpG sites were also reduced in both HER2-positive and HER2-negative BC compared with benign breast tumours, but were more significant in HER2-positive BC (all p-values ≤7.98E–07; Figure 3c, Table S7).